BioCentury
ARTICLE | Product R&D

Neo wave

Why the neoantigen field thinks it won’t go the way of traditional cancer vaccines

March 16, 2017 10:27 PM UTC
””

The central thesis in the increasingly hot field of neoantigens is to pick mutations from patient tumors and turn them into personalized immunotherapies. While companies are staking out their space by defining how they will identify and deliver the neoantigens, they share the goal of generating responses that distance the new class from the poor results of traditional cancer vaccines.

The field will get its first hints this year, as clinical data read out from front-runner companies...